Clinical Trial Update: Randomized Phase 2 With CpG-ODN in Malignant Glioblastoma [Phase 2]

View source ↗

Summary

A randomized Phase 2 trial evaluating CpG-ODN in glioblastoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• CpG-ODN (CpG oligodeoxynucleotide)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Glioblastoma | Phase 2 | Status: COMPLETED